Dr. Xia Yunfei (夏云飞) - Chief Physician & Professor of Radiation Oncology at Sun Yat-sen University Cancer Center

About Prof. Xia Yunfei

Prof. Xia Yunfei (夏云飞) is one of China's premier radiation oncologists, serving as Chief Physician, Professor, Doctoral Supervisor, and Principal Investigator (PI) at the State Key Laboratory of Oncology in South China at Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou. He also serves as Vice Chairman of the Radiation Oncology Professional Committee of the Chinese Research Hospital Association. Nationally and internationally acknowledged as an elite authority on nasopharyngeal carcinoma (NPC), Prof. Xia has dedicated over thirty years to refining radiotherapy techniques, elucidating radioresistance mechanisms, and advancing precision radiation oncology.

Based at SYSUCC—the world's highest-volume and leading research center for head and neck cancers—Prof. Xia has bridged laboratory breakthroughs with clinical radiation delivery, pioneering patient-tailored radiotherapy subtyping and organ-sparing treatment regimens that maximize tumor control while minimizing long-term radiation complications.

Core Clinical Specializations & Oncological Innovations

1. Precision Radiotherapy Subtyping for Nasopharyngeal Carcinoma (NPC)

Traditional staging systems often fail to account for biological heterogeneity within the same clinical tumor stage. Prof. Xia has spearheaded precision radiotherapy classification models that integrate anatomical staging, Epstein-Barr Virus (EBV) DNA dynamics, and multi-omic biomarkers. This enables personalized radiation field delineation and customized dose delivery tailored specifically to the patient's individual biological risk profile.

2. Overcoming Radioresistance & DNA Damage Repair Research

Radiation resistance is the primary barrier to long-term cure in locally advanced and recurrent NPC. As a Principal Investigator at the State Key Laboratory of Oncology in South China, Prof. Xia's laboratory investigates the intricate mechanisms governing tumor cell radioresistance, DNA double-strand break repair pathways, and cellular senescence. His findings have translated into potent radiation sensitizers and synergistic therapeutic regimens that overcome treatment-resistant cancer cells.

3. "Toxicity-Reducing & Efficacy-Enhancing" Regimens for Metastatic NPC

For patients facing distant metastatic and recurrent nasopharyngeal carcinoma, aggressive chemotherapy and re-irradiation often carry prohibitive systemic toxicity. Prof. Xia formulated an innovative "toxicity-reducing and efficacy-enhancing" (减毒增效) combined chemotherapy and radiotherapy protocol. By optimizing drug sequencing, dosage intervals, and precision intensity-modulated radiotherapy (IMRT/VMAT), this approach achieves high objective response rates and prolonged survival while significantly reducing severe mucosal, hematologic, and neurovascular toxicities.

4. Organ-Sparing Intensity-Modulated Radiotherapy & Re-Irradiation

Treating nasopharyngeal tumors requires delivering curative radiation doses mere millimeters from critical neural and vascular structures—including the brainstem, temporal lobes, optic chiasm, and carotid arteries. Prof. Xia is a master of sub-millimeter target delineation, stereotactic body radiation therapy (SBRT), and high-precision re-irradiation protocols for recurrent tumors, successfully preserving swallowing, speech, visual, and cognitive functions.

Academic Leadership, Research & Landmark Publications

Prof. Xia is a prolific scientist whose clinical investigations have consistently advanced the standard of care for head and neck oncology worldwide:

• High-Impact Publications: Prof. Xia has published extensive groundbreaking papers as senior corresponding author in prestigious peer-reviewed medical journals, including JAMA Network Open, Radiotherapy and Oncology (the Official Journal of ESTRO), and Cell Death & Differentiation.
• Series Research on Radiotherapy Subtyping (2024–2025): Throughout 2024 and 2025, his research group produced a landmark series of studies unravelling the molecular drivers of nasopharyngeal metastasis, DNA repair pathways, and clinical trial validations of reduced-toxicity systemic combinations.
• National Clinical Leadership: As Vice Chairman of the Radiation Oncology Professional Committee of the Chinese Research Hospital Association, Prof. Xia actively shapes radiation oncology training, clinical guidelines, and consensus statements across major Chinese tertiary cancer centers.

Sun Yat-sen University Cancer Center (SYSUCC) Profile

Sun Yat-sen University Cancer Center in Guangzhou is recognized worldwide as the epicenter of nasopharyngeal carcinoma diagnosis, clinical research, and multimodal management. As a National Cancer Center consistently ranked among the top three oncology hospitals in China, SYSUCC houses Asia's most sophisticated radiotherapy delivery fleet—including state-of-the-art intensity-modulated radiotherapy (IMRT), volumetric modulated arc therapy (VMAT), stereotactic radiotherapy systems, and advanced molecular imaging—treating thousands of international and domestic patients annually.

Why International Patients Choose Prof. Xia Yunfei

• Decades of Sub-Specialized NPC Mastery: High-volume radiation oncology experience translates directly into superior target contouring, lower recurrence rates, and superior functional preservation.
• Gentler, Smarter Treatment Options: Prof. Xia's "toxicity-reducing and efficacy-enhancing" therapeutic framework provides genuine therapeutic alternatives for fragile, pre-treated, or metastatic patients.
• Pioneering Solutions for Recurrence: Patients deemed ineligible for further radiation at overseas centers benefit from Prof. Xia's specialized re-irradiation and radiation-sensitization protocols.
• Direct Integration with National Key Laboratories: Access to the diagnostic and molecular capabilities of the State Key Laboratory of Oncology in South China ensures precision biomarker-driven care.

The Patient Journey: Navigating Care with CMCS

China Medical Concierge – Shanghai (CMCS) provides dedicated, end-to-end medical concierge support for overseas patients seeking care with Prof. Xia Yunfei at Sun Yat-sen University Cancer Center in Guangzhou:

• Step 1: Imaging & Radiation Plan Review: Patients securely submit DICOM digital imaging files (nasopharyngeal MRI, CT, PET-CT) and pathology records for preliminary specialist review.
• Step 2: Multidisciplinary Feasibility Evaluation: Our team coordinates an initial clinical assessment to evaluate whether targeted radiotherapy, re-irradiation, or modified systemic regimens are indicated.
• Step 3: Visa, Travel & Local Logistics: CMCS handles medical visa documentation, local transit coordination in Guangzhou, airport reception, and comfortable long-stay lodging near SYSUCC.
• Step 4: Clinical Translation & Treatment Navigation: A bilingual medical liaison accompanies you during radiation planning simulations, mold preparation, daily treatment sessions, and specialist appointments.
• Step 5: Post-Treatment Monitoring & Recovery: We coordinate nutritional support, oral mucosal care protocols, and long-term remote imaging follow-up upon return home.

Frequently Asked Questions

What is the benefit of radiotherapy subtyping in nasopharyngeal carcinoma?

Subtyping allows radiation oncologists to tailor radiation fields and doses precisely according to each patient's molecular and anatomical risk profile. Low-risk patients can avoid overtreatment and unnecessary toxicities, while high-risk patients receive intensified, targeted radiation combined with novel radiosensitizers.

Can patients with distant metastatic NPC benefit from radiotherapy?

Yes. Contemporary multimodal strategies show that when systemic disease is controlled, consolidating radiation to the primary nasopharyngeal site and oligometastatic lesions significantly prolongs overall survival and enhances quality of life. Prof. Xia's reduced-toxicity protocols make this feasible even for advanced stages.

What if I have already received radiotherapy and experienced recurrence?

Re-irradiation of the nasopharynx is a highly complex procedure requiring specialized expertise due to cumulative radiation limits of normal surrounding tissues. Prof. Xia is a recognized specialist in secondary radiation mapping, evaluating feasibility using advanced imaging to protect critical neural and vascular structures.

How long does a course of radiotherapy take in Guangzhou?

A standard curative radiation schedule typically comprises 30 to 33 daily fractions over 6 to 7 weeks, preceded by 5 to 7 business days for customized immobilization mask fabrication, high-resolution CT/MRI simulation, and precision treatment planning.

Schedule Your Consultation with Prof. Xia Yunfei

If you or a loved one requires an authoritative second opinion or advanced radiation oncology treatment for nasopharyngeal carcinoma or head and neck cancer, contact our medical concierge team to initiate your consultation.

Contact CMCS Medical Concierge:

• Email: contract@medicalsh.com
• WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
• Website: www.medicalsh.com